UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: TOMONO5

In re Application of:

TOMONO et al.

Appln. No.: 10/573,381

Appln. No.: 10/573,381

Filed: March 24, 2006

For: POLYPEPTIDE HAVING
RNASE III ACTIVITY

Atty. Docket: TOMONO5

Conf. No.:

Art Unit:

Washington, D.C.

June 20, 2006

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building, Mail Stop Amendments 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application; and before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.
- [X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR

§1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below

- [X] A. Document(s) <u>AA</u> is deemed substantially cumulative to document(s) <u>AD</u>, and, in accordance with 37 CFR §1.98(c), a copy of each of the former document(s) is not enclosed.
- [X] 3. Document(s) <u>AE</u> is not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:
- [X] For document \underline{AE} , a corresponding English-language patent or published application (document \underline{AB}) is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.
- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Allen C. Yun

Registration No. 37,971

ACY:pp

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197

Facsimile: (202)737-3528

G:\BN\A\Aoyb\Tomono5\Pto\2006-06-20 IDS.doc

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	10/573,381	- VA	
INFORMATION DISCLOSURE				Filing Date	March 24, 2006	R JIII	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Jun TOMONO e		
				Group Art Unit	(a)	7000 80	
(use as many sheets as necessary)			ecessary)	Examiner Name	/		
Sheet	1	of		Attorney Docket Number	TOMONO5	MARK OFFICE	

		•		U.S. PA	TENT DOCUMENTS	
	Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
1			US-2002/0162126 A1	10-31-2002	BEACH et al.	
4		AB	US-6,479,260 B1	11-12-2002	TAKAYAMA et al.	
ı		AC	US-6,506,559 B1	01-14-2003	FIRE et al.	
			US-			

	FOREIGN PATENT DOCUMENTS						
	Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
		AD	WO 01/68836	09-20-2001	GE-NETICA INC. COLD SPRING HARBOR LABORATORY		
4		ΑE	WO 99/27117	06-03-1999	TAKARA SHUZO CO., LTD.		Υ

	NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
	AF	AMARASHINGHE et al., Escherichia coli ribonuclease III: Affinity purification of hexahistidine-tagges enzyme and assays for substrate binding and cleavage, Methods in Enzymology, 342:143-158 (2001)				
	AG	BERNSTEIN et al., Role for a bidentate ribonuclease in the initiation step of RNA interference, <i>Nature</i> , 409(6818)363-366 (2001)				
	АН	KNIGHT et al., A role the Rnase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis elegans, Science, 293(5538)2269-2271 (2001)				
	Al	ZHANG et al., Human dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP, <i>The EMBO Journal</i> , 21(21)5875-5885 (2002)				
	AJ	OHTANI et al., Heat labile ribonuclease HI from a psychrotrophic bacterium: gene cloning, characterization and site-directed mutagenesis, <i>Protein Engineering</i> , 14(12)975-982 (2001)				
	AK	WELKER et al., Cloning, overexpression, purification, and physicochemical characterization of a cold shock protein homolog from the hyperthermophilic bacterium <i>Thermotoga maritime</i> , <i>Protein Science</i> , 8:394-403 (1999)				
	AL	IUBMB Enzyme Nomenclature EC 3.1.26.3 (1978)				
	AM	GUO et al., par-1, a gene required for establishing polarity in <i>C. elegans</i> embryos, encodes a putative Ser/Thr kinase that is asymmertrically distributed, <i>Cell</i> , 81:611-620 (1995)				
	AN	FIRE et al., Ptent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391:806-811 (1998)				
	AO	TABARA et al., The dsRNA binding protein RDE-4 interacts with RDE-1, DCR-1, and a DexH-Box helicase to direct RNAi in C. elegans, Cell, 109:861-871 (2002)				
	AP	LEE et al., Family of the major cold-shock protein, CspA (CS7.4), of Escherichia coli, whose members show a high sequence similarity with the eukaryotic Y-box binding proteins, Molecular Microbiology, 11(5)833-839 (1994)				
	AQ	WILLIMSKY et al., Characterization of cspB, a Bacillus subtilis inducible cold shock gene affecting cell viability at low temperatures, Journal of Bacteriology, 6326-6335 (1992)				

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.